Hong Kong Stock Alert | ASCLETIS-B (01672) Surges Over 7% Again as Company Plans Up to HK$300 Million Share Buyback Program with Multiple Catalysts Expected in Second Half

Stock News

Oct 08

ASCLETIS-B (01672) surged over 7% again, up 6.8% to HK$11.62 at press time with turnover reaching HK$56.46 million. On the news front, Ascletis announced that its board of directors has decided to exercise the repurchase mandate and will conduct share repurchases in the open market from time to time based on market conditions, using up to HK$300 million for the proposed share buyback program.

Securities analysts previously noted that the company has multiple catalysts in the second half, with several important clinical data readouts imminent. Based on clinical trial progress and company announcements, they expect that Q4 2025 will see topline data from ASC30 oral Phase II, ASC47 Phase I, and ASC50 Phase I trials, while Q1 2026 will see topline data from ASC30 subcutaneous injection Phase II trial. Additionally, the company expects to submit 2-3 new pipeline INDs to the FDA within the next 6-9 months, including a dual-target peptide weight management pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1145788115"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1145788115\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1145788115?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 15:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145788115","market":"fut","top_or_hot":-1,"title":"Hong Kong Stock Alert | ASCLETIS-B (01672) Surges Over 7% Again as Company Plans Up to HK$300 Million Share Buyback Program with Multiple Catalysts Expected in Second Half","media":"Stock News","content":"<p>ASCLETIS-B (01672) surged over 7% again, up 6.8% to HK$11.62 at press time with turnover reaching HK$56.46 million. On the news front, Ascletis announced that its board of directors has decided to exercise the repurchase mandate and will conduct share repurchases in the open market from time to time based on market conditions, using up to HK$300 million for the proposed share buyback program.</p>\n<p>Securities analysts previously noted that the company has multiple catalysts in the second half, with several important clinical data readouts imminent. Based on clinical trial progress and company announcements, they expect that Q4 2025 will see topline data from ASC30 oral Phase II, ASC47 Phase I, and ASC50 Phase I trials, while Q1 2026 will see topline data from ASC30 subcutaneous injection Phase II trial. Additionally, the company expects to submit 2-3 new pipeline INDs to the FDA within the next 6-9 months, including a dual-target peptide weight management pipeline.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Alert | ASCLETIS-B (01672) Surges Over 7% Again as Company Plans Up to HK$300 Million Share Buyback Program with Multiple Catalysts Expected in Second Half</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Alert | ASCLETIS-B (01672) Surges Over 7% Again as Company Plans Up to HK$300 Million Share Buyback Program with Multiple Catalysts Expected in Second Half\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-08 15:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASCLETIS-B (01672) surged over 7% again, up 6.8% to HK$11.62 at press time with turnover reaching HK$56.46 million. On the news front, Ascletis announced that its board of directors has decided to exercise the repurchase mandate and will conduct share repurchases in the open market from time to time based on market conditions, using up to HK$300 million for the proposed share buyback program.</p>\n<p>Securities analysts previously noted that the company has multiple catalysts in the second half, with several important clinical data readouts imminent. Based on clinical trial progress and company announcements, they expect that Q4 2025 will see topline data from ASC30 oral Phase II, ASC47 Phase I, and ASC50 Phase I trials, while Q1 2026 will see topline data from ASC30 subcutaneous injection Phase II trial. Additionally, the company expects to submit 2-3 new pipeline INDs to the FDA within the next 6-9 months, including a dual-target peptide weight management pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4614","symbol_name":"Manus概念股","start_time":0,"source_url":"","article_id":"1145788115","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145788115","pubTimestamp":1759907300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCLETIS-B (01672) surged over 7% again, up 6.8% to HK$11.62 at press time with turnover reaching HK$56.46 million. On the news front, Ascletis announced that its board of directors has decided to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4614":"Manus概念股","YANG":"三倍做空富时中国ETF-Direxion","01672":"歌礼制药-B","BK1515":"抗疫概念","HSCEI":"国企指数","BK1161":"生物科技","BK1191":"制药","07226":"南方两倍做多恒科","BK1574":"生物医药B类股","01477":"欧康维视生物-B"},"translate_title":"港股快讯|歌礼-B(01672)再涨超7%公司拟最多3亿港元股份回购计划下半年料有多重催化剂","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"01672":1,"07226":1,"HSCEI":1,"YANG":1},"content_text":"ASCLETIS-B (01672) surged over 7% again, up 6.8% to HK$11.62 at press time with turnover reaching HK$56.46 million. On the news front, Ascletis announced that its board of directors has decided to exercise the repurchase mandate and will conduct share repurchases in the open market from time to time based on market conditions, using up to HK$300 million for the proposed share buyback program.\nSecurities analysts previously noted that the company has multiple catalysts in the second half, with several important clinical data readouts imminent. Based on clinical trial progress and company announcements, they expect that Q4 2025 will see topline data from ASC30 oral Phase II, ASC47 Phase I, and ASC50 Phase I trials, while Q1 2026 will see topline data from ASC30 subcutaneous injection Phase II trial. Additionally, the company expects to submit 2-3 new pipeline INDs to the FDA within the next 6-9 months, including a dual-target peptide weight management pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}